Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia
The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in patient admitted with Community-acquired pneumonia.
The hypothesis is: Prednisolone in combination with antibiotic treatments is effective in improving clinical outcome in patients hospitalized with CAP.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids|
- Clinical efficacy at the end of treatment
- Clinical efficacy at follow up
- Inflammation response (serummarkers)
- Length of Stay
- Time to clinical stability
- Time to defeverescence
|Study Start Date:||August 2005|
|Study Completion Date:||September 2008|
|Primary Completion Date:||August 2008 (Final data collection date for primary outcome measure)|
Community-acquired pneumonia (CAP) is a acute illness with a considerable morbidity and mortality, especially patients with severe CAP. In the past decennia, in spite of many investigations, little reduction is seen in morbidity an mortality. Corticosteroids have a immune-modulation effect, which is not completely elucidated. Most likely the immune modulation effect is due to down-regulation of pro-inflammatory cytokines. The use of corticosteroids next to antibiotics in CAP could lead to shorter time to clinical stability, length of stay and costs.
Comparison: Hospitalized patients with CAP treated with antibiotics and prednisolone versus hospitalized patients with cap treated with antibiotics and placebo
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170196
|Medisch Centrum Alkmaar|
|Alkmaar, Noord-Holland, Netherlands, 1815 JD|
|Principal Investigator:||Dominic Snijders, Drs||Pulmo Science|
|Study Director:||Wim G Boersma, dr||Pulmo Science|